RXRX Q3 2021 Earnings — Recursion Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RXRXRecursion Pharmaceuticals, Inc.

$2B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M+190.0% YoY

Gross Profit

$3M100.0% margin

Operating Income

-$46M-1856.1% margin

Net Income

-$47M-1897.1% margin

EPS (Diluted)

$-0.28

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

-$33M

Free Cash Flow

-$43M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$659M

Total Liabilities

$60M

Stockholders' Equity

$599M

Cash & Equivalents

$395M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$862,000	+190.0%
Gross Profit	$3M	$862,000	+190.0%
Operating Income	-$46M	-$22M	-106.5%
Net Income	-$47M	-$24M	-98.7%

Revenue Segments

License and Service

$3M99%

Grant

$34,0001%